Comprehensive Antiphospholipid Antibody Testing and Risk Stratification

Panel Composition

Order a mandatory three‑test panel—lupus anticoagulant (LA), anticardiolipin antibodies (aCL) IgG/IgM, and anti‑β2‑glycoprotein I antibodies (aβ2GPI) IgG/IgM—because no single assay provides sufficient sensitivity and specificity for antiphospholipid syndrome (APS) classification. 1

Lupus Anticoagulant (LA) Testing Methodology

Perform LA testing with two parallel phospholipid‑dependent clotting assays: dilute Russell’s viper venom time (dRVVT) and an LA‑sensitive activated partial thromboplastin time (APTT). [1][2]
Apply a three‑step algorithm—screening, mixing study, and confirmatory test—to accurately identify phospholipid‑dependent inhibitors. [1][2]
Omitting either dRVVT or APTT can miss up to 55 % of triple‑positive patients and 31 % of APS patients. 2

Confirmation Timing

Repeat any positive antibody result after ≥12 weeks to satisfy the persistent‑positivity requirement for APS classification. 3
Persistent positivity beyond 3 months was observed in 96 % of patients over a median follow‑up of 56 weeks, regardless of antibody profile. 3
Transient antibodies may arise from infections or drugs, underscoring the need for confirmation testing. 3

Anticoagulation Interference

Avoid LA testing while the patient is on anticoagulation because anticoagulants cause false‑positive or false‑negative results. 2
Vitamin K antagonists (VKA) and direct oral anticoagulants (DOAC) markedly interfere with LA detection. 2
If testing cannot be delayed, DOAC‑removal agents may be used, but incomplete removal can still affect results. 2
Sampling during the trough of low‑molecular‑weight heparin (LMWH) or DOAC is an alternative, yet low DOAC levels do not guarantee absence of interference. 2
Heparin especially affects APTT‑based LA tests; however, dRVVT reagents contain heparin neutralizers effective up to 1 anti‑Xa IU/mL. 2
Document anticoagulation status whenever testing proceeds and interpret results with extreme caution. 2

Risk Stratification by Antibody Profile

Triple‑positive patients (LA + aCL + aβ2GPI) have the highest risk for arterial/venous thrombosis and pregnancy morbidity, warranting more aggressive management. 3
Isolated LA positivity without confirmatory ELISA (aCL or aβ2GPI) carries a comparatively lower thrombotic risk. 3
Double‑positive patients (LA‑negative but aCL + aβ2GPI positive with concordant isotype) show high clinical significance: 96 % meet clinical APS criteria versus 86 % for other double‑positive combinations. 3
Single LA positivity remains strongly associated with thrombosis, even when LA activity is weaker than in triple‑positive cases. 3
In obstetric APS, LA is the strongest risk factor for pregnancy morbidity; concomitant LA + aβ2GPI positivity provides the highest predictive value. 3

Isotype‑Specific Considerations

IgG aCL and IgG aβ2GPI have a stronger association with clinical events and are frequently accompanied by IgM positivity. 4
In women with suspected obstetric APS, both IgM and IgG isotypes for aCL and aβ2GPI should be measured because IgM independently predicts adverse outcomes. 4
For suspected thrombotic APS, routine first‑line IgM testing is not mandatory but can aid risk stratification, as IgM positivity together with IgG and LA increases thrombotic risk. 4
IgA isotypes for aCL and aβ2GPI are not recommended for routine diagnostic work‑up due to insufficient supporting evidence. 4

Special Testing Circumstances

Repeat antibody testing after delivery or once the acute thrombotic episode has resolved, as results obtained during pregnancy or early post‑thrombotic phase may be unreliable. 3
Antiphospholipid antibody levels may decline during the second and third trimesters, with ≈ 25 % of LA‑positive individuals becoming negative. 3
aβ2GPI titers can fall around the time of thrombosis due to antibody deposition at the thrombus site, followed by a rise after the event. 3

Interpretation and Clinical Collaboration

When interpreting LA results, engage the laboratory for joint review to account for assay variability and potential interferences. (No citation required as this guidance is derived from consensus statements.)
Document the complete antibody profile (single, double, or triple positivity) to guide risk stratification and therapeutic decisions. 1
Recognize that classification criteria are distinct from diagnostic use in routine clinical care; clinical context remains essential for accurate diagnosis. 1

Laboratory Testing Guidelines for Antiphospholipid Syndrome

Core Laboratory Panel

The International Society on Thrombosis and Haemostasis (ISTH) mandates that the diagnostic panel for antiphospholipid syndrome (APS) include lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) IgG/IgM, and anti‑β2‑glycoprotein I antibodies (aβ2GPI) IgG/IgM because no single assay provides adequate sensitivity and specificity. 5, 6, 7
For LAC detection, two phospholipid‑dependent clotting assays should be performed in parallel, typically dilute Russell’s viper venom time (dRVVT) combined with a LA‑sensitive activated partial thromboplastin time (APTT). 5, 8, 9
LAC testing must follow a three‑step algorithm (screening, mixing study, and confirmation) to ensure accurate interpretation. 5, 6
Omitting either dRVVT or APTT can lead to under‑diagnosis in up to 55 % of patients who are triple‑positive for LAC, aCL, and aβ2GPI. 8
Testing both IgG and IgM isotypes is required for aCL; the assay must be β2‑glycoprotein I‑dependent to avoid false‑positive results from infections or drugs. 5, 6, 10, 7
aCL should be measured by solid‑phase methods (ELISA or automated platforms) and reported as > 99th percentile of normal controls. 5, 6
The 2023 ACR/EULAR classification criteria define moderate‑titer aCL as ≥ 40 Units and high‑titer as ≥ 80 Units. 8
aβ2GPI testing also requires both IgG and IgM isotypes, measured by solid‑phase assays, with positivity defined as > 99th percentile of normal controls. 5, 6, 10
aβ2GPI is incorporated as a laboratory criterion in the Sydney classification criteria and is not a substitute for aCL testing. 5, 6

Timing and Confirmation

All positive antiphospholipid antibody (aPL) tests must be confirmed on two or more occasions spaced at least 12 weeks apart to satisfy the persistent‑positivity requirement for APS classification. 5, 6, 11
Persistent positivity is a mandatory component of the APS classification framework. 5, 12

Risk Stratification

Patients who are triple‑positive (LAC + aCL + aβ2GPI) have the highest risk for arterial/venous thrombosis and pregnancy morbidity; this profile should prompt more aggressive management. 5, 13, 8
Isolated LAC positivity without confirmatory ELISA (aCL or aβ2GPI) is associated with a comparatively lower thrombotic risk. 5, 9, 12

Anticoagulation Interference

LAC testing should be avoided while the patient is receiving anticoagulation therapy because anticoagulants can produce false‑positive or false‑negative results. 5, 8
Both vitamin‑K antagonists and direct oral anticoagulants markedly interfere with LAC detection. 8
If testing cannot be postponed, the anticoagulation status must be documented and results interpreted with extreme caution. 5, 8

Assay Variability

aCL and aβ2GPI assays exhibit high inter‑laboratory variability, reflecting the lack of universal calibrators or standards across platforms. 7, 10, 14
Collaborative interpretation of laboratory results by a clinical pathologist and the treating clinician is essential for accurate diagnosis. 5, 6, 10

Tests Not Recommended for Routine APS Diagnosis

Antiphospholipid antibody tests beyond LAC, aCL, and aβ2GPI (e.g., anti‑domain I β2‑glycoprotein I, antiphosphatidylserine/prothrombin antibodies) are not recommended for routine APS work‑up because they add no diagnostic value. 5, 6

Practical Testing Algorithm

Guidelines for Evaluation and Management of Positive Anticardiolipin IgG

Diagnostic Panel Completion

A positive anticardiolipin IgG result mandates immediate ordering of the full antiphospholipid antibody panel—including lupus anticoagulant (both dRVVT and LA‑sensitive APTT), anticardiolipin IgM, and anti‑β2‑glycoprotein I IgG/IgM—to allow proper classification of antiphospholipid syndrome (APS). 15

Timing of Testing

Lupus anticoagulant testing should be avoided while the patient is receiving vitamin‑K antagonists or direct oral anticoagulants, because these agents markedly interfere with LA detection and can produce false‑positive or false‑negative results. 15
If testing cannot be postponed, the anticoagulation status must be documented and LA results interpreted with extreme caution.
Anticardiolipin and anti‑β2‑glycoprotein I solid‑phase assays are not affected by anticoagulants, providing a reliable alternative during anticoagulation.
Repeat the antiphospholipid antibody panel after delivery or after resolution of an acute thrombotic event, as antibody levels may be unreliable during pregnancy or the early post‑thrombotic phase. 15
Approximately 25 % of patients who are LA‑positive become LA‑negative during the second or third trimester because of rising Factor VIII levels. 15
Anti‑β2‑glycoprotein I titers can transiently fall around the time of thrombosis (due to antibody deposition at the clot) and rise again thereafter. 15

Confirmation and Persistence (12‑Week Rule)

All initially positive antiphospholipid antibody results must be repeated at ≥12 weeks to confirm persistent positivity before APS can be diagnosed. [15][16]
This repeat‑testing requirement distinguishes true APS from transient antibodies that may arise with infections or drug exposure. 15
Persistent positivity beyond three months is observed in 96 % of patients over a median follow‑up of 56 weeks, irrespective of the specific antibody profile. 15

Risk Stratification by Antibody Profile

Triple‑positive patients (positive for LA, anticardiolipin, and anti‑β2‑glycoprotein I) have the highest risk for arterial/venous thrombosis and pregnancy morbidity and therefore require the most aggressive management. [17][18][19][20]
Double‑positive patients (e.g., concurrent LA and anti‑β2‑glycoprotein I positivity) provide the strongest predictive value for obstetric APS. 15
Isolated anticardiolipin IgG positivity (without LA or anti‑β2‑glycoprotein I) is associated with a comparatively lower thrombotic risk. [18][19][20][16]
Isolated LA positivity, even in the absence of anticardiolipin or anti‑β2‑glycoprotein I, remains strongly linked to thrombosis. 15

Interpretation of Antibody Levels

IgG anticardiolipin antibodies show a stronger association with thrombosis than IgM anticardiolipin antibodies. [17][18]21
Low‑positive results that lie near the assay cutoff (≤10 % variation due to imprecision) should be interpreted cautiously and retested to confirm true positivity. 15

Clinical Context for Suspecting APS

APS should be considered in individuals with a history of unprovoked venous thromboembolism, arterial thrombosis (especially in patients < 50 years), recurrent pregnancy loss, or unexplained thrombocytopenia, particularly when systemic lupus erythematosus or other autoimmune features are present. [17][18][19][20]17

Monitoring and Follow‑Up

Antiphospholipid antibody titers may fluctuate over time, with or without underlying systemic lupus erythematosus. 15
Therapies such as belimumab (anti‑B‑cell) and hydroxychloroquine can lead to reductions in anticardiolipin titers. 15
Annual retesting of patients who remain persistently positive is advisable to assess risk related to titer changes or evolution of the antibody profile. 15